Please login to the form below

Not currently logged in
Email:
Password:

Orexigen

This page shows the latest Orexigen news and features for those working in and with pharma, biotech and healthcare.

Takeda files block on generic diet pill launch

Takeda files block on generic diet pill launch

Orexigen and its partner Takeda have taken Actavis to court to block a generic version of the firms' diet pill Contrave. ... The lawsuit alleges that the generic drugmaker Actavis has infringed patents on Orexigen and Takeda's new weight-loss treatment

Latest news

  • Saxenda debuts in US with $1,000-a-month price tag Saxenda debuts in US with $1,000-a-month price tag

    The Danish drugmaker has launched Saxenda in the US at a price of just over $1, 000 per month, significantly more than other recently-launched obesity drugs such as

  • Positive data in Saxenda diabetes prevention study Positive data in Saxenda diabetes prevention study

    the US of three other drugs; Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion). ... None of these has made significant headway since their US launches, and of the three only

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    new products - Eisai and Arena's Belviq (lorcaserin), Vivus' Qsymia (phentermine/topiramate) and Orexigen's Contrave (naltrexone and bupropion) in the last couple of years in the US and other world ... markets. The picture in Europe is different, however,

  • FDA approval for Novo Nordisk's obesity shot FDA approval for Novo Nordisk's obesity shot

    1999. In the last two years three other drugs have gained US marketing approval, including: Orexigen's Contrave, Vivus' Qsymia (phentermine/topiramate) and Arena Pharmaceuticals' Belviq (lorcaserin).

  • Orexigen’s obesity pill Mysimba set for European approval Orexigen’s obesity pill Mysimba set for European approval

    The drug efficacy and safety arm of the European Medicines Agency has recommended Orexigen Therapeutics' new anti-obesity drug Mysimba for certain patients to help them lose weight. ... The drug is a combination of the antidepressant bupropion and

More from news
Approximately 4 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Mark Booth joins Probiodrug Mark Booth joins Probiodrug

    Booth joins the Alzheimer's disease specialty biopharmaceutical firm from Orexigen Therapeutics, where he served as chief commercial officer leading its business development and investor relations activities.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics